Core Insights - Fennec Pharmaceuticals achieved record annual revenue with net product sales of $44.6 million for the fiscal year 2025, reflecting a 50% year-over-year growth, and Q4 2025 net product sales of $13.8 million, representing a 75% increase over Q4 2024 [1][8][9] - The company executed a clinical data strategy to expand real-world validation of its product PEDMARK across new tumor types and patient populations through independent research [1][4] - Fennec reported strong patient enrollments and conversion rates in Q4 2025, indicating effective field execution and growing adoption of PEDMARK [1][3] - The company completed an oversubscribed equity offering of $42 million, enhancing its financial position [1][3] - Positive topline results were announced from a clinical study in Japan evaluating PEDMARK for reducing cisplatin-induced hearing loss [1][5] Financial Performance - For Q4 2025, net product sales were $13.8 million, up from $7.9 million in Q4 2024, marking a 75% increase [8][10] - Full-year net product sales reached approximately $44.6 million, compared to $29.6 million in 2024, a 50% increase [8][10] - Selling and marketing expenses for Q4 2025 were $6.1 million, up from $3.9 million in Q4 2024, primarily due to increased payroll and marketing efforts [8][10] - General and administrative expenses for Q4 2025 were $8.9 million, compared to $4.2 million in Q4 2024, driven by higher legal and payroll costs [8][10] - Cash and cash equivalents stood at $36.8 million as of December 31, 2025, reflecting a $10.2 million increase from the previous year [8][11] Business Highlights - Continued growth in key PEDMARK accounts, with increasing adoption among adolescent and young adult (AYA) patients across various tumor types [4][5] - Expansion of the field team to enhance customer engagement and support more cancer patients in protecting their hearing [4] - New real-world data presented at the 2026 Multidisciplinary Head and Neck Cancers Symposium indicated the safe administration of PEDMARK in adults with head and neck cancer [4][5] - Initiation of two institution-led clinical studies evaluating PEDMARK for preventing cisplatin-induced ototoxicity in adult cancer patients [4][5] Upcoming Events - Management will host one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 15-16, 2026 [6]

Core Insights - The study demonstrated that PEDMARK significantly reduces hearing loss in pediatric patients aged 3-18 years receiving cisplatin, with rates of 24% and 16% for hearing loss compared to historical rates of 56-63% in cisplatin-only groups [1][2][4] - PEDMARK did not interfere with the antitumor activity of cisplatin, showing a clinical response rate of approximately 95% [1][3] - The company plans to pursue registration for PEDMARK in Japan and is exploring partnership or licensing opportunities based on these positive results [1][5] Study Details - The STS-J01 clinical trial enrolled 33 patients, including 27 in the primary cohort (ages 3-18) and 6 in exploratory cohorts, focusing on the prevention of cisplatin-induced ototoxicity [6][7] - The primary endpoint was the incidence of hearing impairment at the end of treatment, assessed using ASHA criteria, with secondary endpoints including safety and antitumor efficacy [7] Pharmacokinetics and Safety - Pharmacokinetic analyses indicated no reduction in cisplatin exposure, confirming that PEDMARK does not adversely interact with cisplatin [3] - The study reported over 200 treatment-emergent adverse events, none attributed to PEDMARK, indicating it was well-tolerated [4] Clinical Implications - The findings support the effectiveness of PEDMARK in protecting hearing without compromising the efficacy of cisplatin, addressing a significant unmet medical need in Japan [5] - The results reinforce the global clinical evidence for PEDMARK, demonstrating its protective effect across various settings and tumor types [4] Regulatory and Market Potential - Fennec Pharmaceuticals intends to register PEDMARK in Japan and is seeking licensing opportunities, highlighting the potential for market expansion [1][5] - PEDMARK is the first FDA-approved therapy for reducing cisplatin-induced ototoxicity in pediatric patients, with significant implications for patient quality of life [10][12]

Core Insights - Fennec Pharmaceuticals reported total net revenues of $9.7 million for Q2 2025, reflecting a 33% increase compared to the same quarter in 2024, driven by growth in large community practices and academic centers [1][3][9] - The company has seen a successful uptake of its product PEDMARQSI in the UK and Germany, with plans for additional EU launches [1][3] - The management anticipates results from a clinical trial in Japan (STS-J01) in the second half of 2025, which may lead to registration and potential licensing opportunities [1][3] Financial Performance - Net product sales for Q2 2025 were approximately $9.7 million, up from $7.3 million in Q2 2024, attributed to growth in the adolescent and young adult (AYA) population [9][11] - Selling and marketing expenses decreased to $4.4 million in Q2 2025 from $4.6 million in Q2 2024, while general and administrative expenses increased slightly to $7.0 million from $6.9 million [9][11] - The company reported a net loss of $3.2 million for Q2 2025, compared to a net loss of $5.6 million in Q2 2024 [11] Business Highlights - Fennec's segmentation model and data-driven targeting have led to significant growth in both new and repeat customers, particularly in large community and academic practices [6] - A large national oncology group has added PEDMARK to its formulary for patients under 40, indicating growing recognition of the need to protect younger patients from cisplatin-induced hearing loss [6] - The NCODA PQI issued for PEDMARK aims to provide clinical data and guidance for healthcare professionals managing patients on cancer therapies [6] Upcoming Events - Fennec will ring the NASDAQ closing bell on September 5, 2025, alongside PEDMARK patients and their families [10] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City [10] Product Information - PEDMARK is the first FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients [15][19] - The product has received Orphan Drug Exclusivity in the U.S. and is commercially available in the U.K. and Germany under the brand name PEDMARQSI [28][30]

Core Insights - Fennec Pharmaceuticals reported a significant increase in net product sales for PEDMARK, achieving $29.6 million for the full fiscal year 2024, which is a 40% increase year-over-year, and $7.9 million in Q4 2024, reflecting a 13% increase from the previous quarter [1][11][32] - The company has strengthened its leadership team and is focused on expanding the adoption of PEDMARK in academic institutions and new patient segments, particularly in the adolescent and young adult (AYA) market [3][32] - Fennec has successfully launched PEDMARQSI in the UK and Germany, enhancing global access to its product aimed at preventing cisplatin-induced hearing loss in pediatric patients [1][6][32] Financial Performance - For the fiscal year 2024, total revenue reached $47.5 million, with net product sales contributing $29.6 million, compared to $21.3 million in 2023 [11][12] - The company reported a cash position of $26.6 million as of December 31, 2024, with a notable increase in cash and cash equivalents of $13.4 million from the previous year [11][14] - Selling and marketing expenses increased to $18.4 million for FY 2024, up from $12.1 million in FY 2023, reflecting the company's efforts to expand outreach [11][12] Strategic Developments - Fennec completed an early repayment of $13 million of its convertible debt facility, optimizing its balance sheet and saving approximately $1.5 million in future interest payments [1][6] - The company is advancing its efforts to include PEDMARK in the NCCN Drug and Biologics Compendium, which is crucial for expanding access and reimbursement pathways [6][32] - A clinical trial in Japan (STS-J01) is fully enrolled, with results expected in the second half of 2025, potentially leading to registration of PEDMARK in Japan [1][6]